Lim E, et al. An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with Advanced Breast Cancer. In Press. Breast Cancer Research Treatment.

Wong K, … Lim E, Emmett L. ⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry and feasibility in a phase I trial. Pharmaceuticals 2022, 15(7), 772

Berthelet J, ... Lim E, Charafe-Jauffret E, Ginestier C, Ernst M, Hollande F, Anderson R, Pal B, Yeo B, Davis MJ, Merino D. Computational screening of anti-cancer drugs identifies a non-BRCA1-dependent cisplatin-sensitive signature in breast cancer. Cancers 2022;14(10):2404

RJ Morrow, ... E Lim, CN Johnstone, M Ernst. Paracrine IL‐6 signalling confers proliferation between heterogeneous inflammatory breast cancer sub‐ Cancers. 2022;14(9);2292

Portman N, Lim E. A new sophistication for breast cancer PDX. Nature Cancer. 2022;3;138–40

Haggstrom LR, Vardy JL, Carson EK, Segara D, Lim E*, Kiely BE*. Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review. Cancers. 2022;14(4);920

Brown L, Achinger-Kawecka J, Portman N, Clark S, Stirzaker C*, Lim E*. Epigenetic Therapies and Biomarkers in Breast Cancer. Cancers. 2022;14(3):474

Dinh P, ... Lim E, White M, Mann GB, Pathmanathan N. Impact of the EndoPredict genomic assay on treatment decisions for estrogen receptor positive early breast cancer patients: benefits of physician selective testing. Breast Cancer Research Treatment. 2022 Feb;191(3):501-11

Brown L*, Meredith T*, … Arnott C*, Lim E*. Heart failure therapies for the prevention of HER2-monoclonal antibody mediated cardiotoxicity. Cancers. 2021 Nov 3;13(21):5527

Portman N, Chen J, E Lim. MDM2 as a rational target for intervention in CDK4/6 inhibitor resistant, hormone receptor positive breast cancer. Frontiers Oncology. 2021 Nov 3;11:777867

Nguyen A, … Chen J, Lim E, Emmett L. Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial. Journal of Medical Imaging and Radiation Oncology. 2021 Oct 21

Kumar S, Freelander A, Lim E. Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Cancers 2021 Oct 3:13;4972

Du Q, Smith GC, Luu PL, Ferguson JM, Armstrong NJ, Caldon CE, Campbell E, Nair SS, Zotenko E, CM, Buckley M, Chia KM, Portman N, Lim E, Kaczorowski D, Chan CL, Barton K, Deveson IW, Smith MA, Powell JE, Skvortsova K, Stirzaker C, Achinger-Kawecka J, Clark SJ. DNA methylation is required to maintain both DNA replication timing precision and 3D genome integrity. Cell Reports. 2021 Sep 21;36(12):109722

Wu SZ, Al-Eryani G, Roden D, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy J, Bartonicek N, Wang T, Larsson L, Kaczorowski D, Weisenfeld NI, Uytingco CR, Chew JG, Bent ZW, Chan CL, Gnanasambandapillai V, Dutertre CA, Gluch L, Hui MN, Beith J, Parker A, Robbins E, Segara D, Mak C, Cooper C, Chan B, Warrier S, Ginhoux F, Millar E, Powell J, Williams SR, Liu XS, O’Toole S, Lim E, Lundeburg J, Perou CM, Swarbrick A. An integrated multi-omic cellular atlas of human breast cancers. Nature Genetics. 2021 Sep 6;53:1334–47

Chen J, Colosimo M, Lim E. The management of HER2-positive early breast cancer: current and future therapies. Asia Pacific J Clin Oncol. 2021 Sep 1;17:S6:1-12

Aziz D, Portman N, ... Lim E, Caldon CE. Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. NPJ Cancer. 2021 Aug 31;7;111

Alves CL, Ehmsen S, Terp MG, Portman N, T... Lim E, Ditzel HJ. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature Comms. 2021 Aug 25;12(1):5112

Chew NJ, Lim KS, Nguyen EV, Shin SY, Yang J, Hui MN, Deng NT, McLean CA, Welm AL, Lim E, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Research. 2021 Aug 3;23(1):82

Ardolino L, Lau B, Wilson I, Chen J, Borella L, Stone E, Lim E. Paclitaxel-induced Pneumonitis in Early Breast Cancer: A Single Institution Experience. Frontiers Oncology. 2021 Jun 23;11:701424.

Wu SZ, Roden DL, Al-Eryani G, Bartonicek N, Harvey K, Cazet AS, Chan CL, Junankar S, Hui MN, Millar E, Beretov J, Horvath L, Joshua AM, Stricker P, Wilmott JS, Quek C, Long GV, Scolyer RA, Yeung BZ, Segara D, Mak C, Warrier S, Powell J, O’Toole S, Lim E, Swarbrick, A. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Biol. 2021 May 10;13(1):81.

Freelander A, Brown L, Parker A, Segara D, Portman N, Lau B, Lim E. Molecular biomarkers for contemporary therapies in hormone receptor positive breast cancer. Genes 2021 Feb 17;12(2):285

Hickey TE, Selth LA, Chia KM, Milioli HH, Roden D, Laven-Law G, Jindal S, Hui M, Ebrahimie E, Birrell SN, Stelloo S, Caldon CE, Finlay-Schultz J, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer. Nature Medicine.2021 Feb;27(2):310-20

Chia KM, Freelander A, Kumar S, Portman N, Lim E. Estrogen receptor positive breast cancer patient derived xenograft models in translational research. Current Opinion in Endocrine and Metabolic Research. 2020 Dec;15;31-6

Wu SZ, Roden D, Wang CF, Cazet A, Al-Eryani G, Harvey K, Holliday H, Murphy K, Pereira B, Bartonicek N, Hou R, Torpy J, Junankar S, Hui M, Gluch L, Beith J, Parker A, Robbins E, Segara D, Mak C, Cooper C, Warrier S, Powell J, O’Toole S, Cox T, Timpson P, Forrest A, Lim E, Liu XS, Swarbrick A. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. Embo J. 2020 Oct 1;39(19)

Light M, McFarlane T, Ives A, Shah B, Lim E, et al. Testosterone therapy considerations in estrogen, progesterone and androgen receptor positive breast cancer in a transgender male. Clinical Endo. 2020 Sep;93(3):355-7.

Portman N*, Milioli HH*, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Segara D, Parker A, Haupt A, Haupt Y, Tilley WD, Swarbrick A, Caldon CE*, Lim E*. Synergistic targeting of estrogen-receptor positive breast cancers by MDM2 inhibition in combination with endocrine therapy or CDK4/6 inhibition. Breast Cancer Research. 2020 Aug 12;22(1):87.

Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, et al, Swarbrick A. Proteogenomic analysis of Inhibitor of Differentiation in basal-like breast cancer. Breast Cancer Research. 2020 Jun 11;22(1):63

Milioli HH, Alexandrou S, Lim E, Caldon C. Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine-Related Cancer. 2020 May;27(5):R93-112

Chen J, Easwaralingam N, Warrier S, Mak C, Carson E, Ong A, Snook K, Middleton K, Parker A, Spillane A, Mann B, Lim E*, Segara D.* Window of Opportunity Treatment in Breast Cancer. ANZ J Surg. 2020 Jan;90(1-2):34-40.

Tadesse S. Anshabo AT, Portman N, Lim E, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today. 2019 Dec10.

Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Summary Position Statement. Med J Aus. 2019 Sep;211(5):224-9.

Chi D, Singhal H, Li L, Xiao TF, Liu WH, Pun M, Jeselsohn R, He H, Lim E, et al. Estrogen Receptor Signaling is Reprogrammed During Breast Tumorigenesis. Proc Natl Acad Sci USA. 2019 Jun 4;116(23):11437-43.

Field AS, Raymond WA, Rickard M, Arnold L, Brachtel EF, Chaiwun B, Chen L, Di Bonito L, Kurtycz DFI, Lee AHS, Lim E, et al. The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytology. Acta Cytol. 2019 May 21:1-17

Young AR, Duarte JD, Coulson R, O’Brien M, Deb S, Lopata A, Behren A, Mathivanan S, Lim E, Meeusen E. Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. Cancers. 2019 May 16;11(5).

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE*, Lim E*. Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocr Relat Cancer. 2019 Feb 1;26(2):251-264

Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR and Caldon CE. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Int J Mol Sci. 2019 Feb 4;20(3).

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Res. 2019,21;21(1):43.

Lee KWC, Lord S, Finn RS, Lim E, et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019 Feb;174(1):271-8.

Portman N, Alexandrou S, Carson EK, Wang S, Lim E*, Caldon CE*. Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer. Endocr Relat Cancer. 2019 Jan;26(1):R15-30

Lim E, Beith J, et al. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer. Asia Pacific J Clin Oncol. 2018 Oct;14 Suppl 4:12-21. 

Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E, et al. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on current treatment paradigm. Asia Pacific J Clin Oncol. 2018 Oct;14 Suppl 4:3-11. 

Hastie R, Lim E, et al. Vinorelbine potently induces placental cell death, does not harm fertility and is a potential oral treatment for ectopic pregnancy. EBioMedicine 2018;29:166-76.

Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Larsson C, Eriksson P, Lehn S, Reid S, Saal LH, Anderberg C, Cortez E, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, et al. Microenvironmental control of breast cancer subtype elicited by paracrine platelet derived growth factor-CC signaling. Nature Medicine.2018;24(4):463-73.

Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endo. 2018 Sep;89(3):280-296.

Cazet AS, Hui MH, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng NT, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, et al. Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer. Nature Comms. 2018 Jul 24;9(1):2897

Papachristou E, Kishore K, Holding A, Harvey K, Roumeliotis T, Chilamakuri C, Omarjee S, Chia KM, Swarbrick A, Lim E, et al. Quantitative Multiplexed Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins (qPLEX-RIME) for monitoring the dynamics of chromatin-associated complexes. Nature Comms. 2018 Jun 13;9(1):2311.

Robinson DH, Churilov L, Lin NU, Lim E*, Seah D*. Attitudes of patients with metastatic cancer towards research biopsies. Asia Pacific J Clin Oncol. 2018 Jun;14(3):231-8

Meeusen E, Lim E, Mathivanan S. Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy. Proteomics. 2017 Dec;17:23-4

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Neoadjuvant interferons: Critical for effective PD-1 based immunotherapy in TNBC. Cancer Immunol Res. 2017;5(10):871-84

Lim E, Tarulli G, Portman N, Hickey T, Tilley W, Palmeiri C. Pushing the Estrogen Receptor Around in Breast Cancer. Endocr Relat Cancer. 2017;24(4):R123-44

Haupt S, Vijayakumaran R, Panimaya J, Burgess A, Lim E, Haupt Y. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. 2017;9(1):53-61

Dreijerink K, Groner AC, Vos E, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, et al. Enhancer-mediated oncogenic function of the MEN1 tumor suppressor in breast cancer. Cell Reports. 2017;18(10):2359-72

Law A, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocr Relat Cancer. 2017;24(4):R123-44

Lim E, Johnson SF, Geyer M, Serra V, Shapiro GI. Sensitizing HR-proficient cancers to PARP inhibitors. Molecular Cellular Oncology. 2017 Mar 3;4(6)

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S,  Bernhardy AJ, Coulson R, Lazaro JB, Kachupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D’Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.  CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild type and mutated models of triple negative breast cancer. Cell Reports. 2016;17(9):2367-81

Lim E, Palmieri C, Tilley W. Renewed interest in the Progesterone Receptor in Breast Cancer. British J Cancer. 2016;115(8):909-911

Samanta S, Sun H, Goel HL, Pursell B, Chang C, Khan A, Greiner DL, Cao S, Lim E, Shultz LD, Mercurio AM. IMP3 promotes stem-like properties in Triple-Negative breast cancer by regulating SLUG. Oncogene 2016;35(9):1111-21.

Ramchand S, Lim E, Grossmann M. Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed? Clin Endo. 2016;85(5):689-693

Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical Overview of MDM2/X targeted therapies. Frontiers Onc 2016:6:1-7.

Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645-654.

Portman N, Wahlroos S, Parker A, Segara D, Lim E. Endocrine therapy for breast cancer: A Renaissance. The Endocrinologist. 2016 Dec 01.

Neupane M, Clark A, Landini S, Birkbak N, Eklund A, Lim E, et al. MECP2 Is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy. Cancer Discovery. 2016;6(1):45-58

Wang YB, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, et al. CDK7-dependent transcriptional addiction in Triple-Negative breast cancer. Cell 2015;163(1):174-86.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Commun. 2015;6:8746

Samanta S, Sun H, Goel HL, Pursell B, Chang C, Khan A, Greiner DL, Cao S, Lim E, Shultz LD, Mercurio AM. IMP3 promotes stem-like properties in Triple-Negative breast cancer by regulating SLUG. Oncogene 2016;35(9):1111-21.

Chia KM, O’Brien M, Brown M, Lim E. Targeting the androgen receptor in breast cancer. Current Onc Rep. 2015;17(2):427-34.

Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, et al. A Laminin 511 Matrix is regulated by TAZ and functions as the ligand for the a6Bb1 integrin to sustain breast cancer stem cells. Genes & Devt. 2015;29(1):1-6.

Wang YB, Lee YM, Huang A, Lim E, et al. The oncogenic protein kinase MELK is essential for mitotic progression in basal-like breast cancer cells. Elife. 2014:May20:3:e01763.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, et al. XBP1 promotes triple negative breast cancer by controlling the HIF1α transcriptional program. Nature. 2014:508(7494):103-7.

Hu Y, Petit A, Ficarro S, Toomire KJ, Xie A, Lim E, et al. PARP1-driven Poly-ADP-ribosylation regulates BRCA1 function in homologous recombination mediated DNA repair. Cancer Discovery. 2014;4(12):1430-47.

Lu G, Zhang Q, Huang Y, Song JX, Tomaino R, Ehrenberger T, Lim E, et al. Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014:26(2):222-34.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, et al. XBP1 promotes triple negative breast cancer by controlling the HIF1α transcriptional program. Nature. 2014:508(7494):103-7.

Lim E & Lin NU. Updates on the management of breast cancer brain metastases. Oncology. 2014:28(7):572-8.

Lim E, Ni M, Cao SA, Hazra A, Tamimi R, Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Current Breast Cancer Reports. 2014:6(2):71-8.

Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013:24(3):347-64.

Ni M, Chen YW, Fei T, Li D, Lim E, Liu XS, Brown M. Amplitude modulation of androgen signaling by c- MYC. Genes Dev. 2013:27(7):734-48.

Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, et al. PDEF Promotes Luminal Differentiation 1 and acts as a survival factor for ER positive breast cancer cells. Cancer Cell. 2013;23;753–67.

McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013:24(3):365-78.

Tichy J, Lim E, Anders CK. Adolescent and young adult breast cancer: A review with a focus on biology. J Natl Compr Canc Netw. 2013:11(9):1060-9.

Lim E, Metzger O, Winer EP. Natural history of hormone receptor positive breast cancer. Oncology. 2012:26(8):688-94.

Lim E, Ni Min, Hazra A, Tamini R, Brown M. Elucidating the role of androgen receptors and breast cancer. Clinical Investigation. 2012:2(10):1003-11

Shen R, Zhou A, Kim E, Lim E, Habelhah H, Hahn W. IKKε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012:32(23):4756-68.

Oakes SR, Vaillant F, Lim E, et al. The BH3-mimetic ABT-737 sensitizes BCL-2 expressing breast cancers to chemotherapy, implicating BCL-2 as a predictive biomarker. PNAS 2011:109(8):2766-71.

Ni M, Chen YW, Lim E, Bailey ST, Imai Y, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011:20(1):119-31.

Lim E*, Wu D*, Pal B et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010:12(2):R21.

Wu D*, Lim E*, Vaillant F, et al. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010:26(17):2176-82.

Lim E*, Vaillant F*, Wu D et al. Aberrant luminal progenitors as a likely target population for basal tumor development in BRCA1 mutation carriers. Nature Med. 2009:15(8):842-4.

Lim E, Browning J, MacGregor D, Davis ID, Cebon JS. Antigen expression in desmoplastic melanoma: a comparison of cancer testis antigen with differentiation antigen expression. Melanoma Res. 2006:16(4):347-55.

Lim E, Johns J, McLaughlin S, Faragher I, Skinner I, Chao M, Gibbs P. Subsite-specific colorectal cancer in diabetic and nondiabetic patients. Cancer Epidemiol Biomarkers Prev. 2005:14(6):1579-82.